BSE Live
Mar 13, 16:01Prev. Close
12.38
Open Price
12.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:58Prev. Close
12.40
Open Price
12.40
Bid Price (Qty.)
12.06 (45)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Syncom Formulations (in Rs. Cr.) | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 16.20 | 16.49 | 13.93 | 8.45 | 0.00 | |
| Net CashFlow From Operating Activities | 24.17 | 0.08 | 6.73 | 5.78 | 0.00 | |
| Net Cash Used In Investing Activities | -22.85 | 0.74 | -4.28 | -0.32 | 0.00 | |
| Net Cash Used From Financing Activities | -2.41 | 0.68 | -0.93 | -6.38 | 0.00 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -1.08 | 1.50 | 1.52 | -0.92 | 0.00 | |
| Cash And Cash Equivalents Begin of Year | 6.77 | 5.28 | 3.76 | 4.68 | 0.00 | |
| Cash And Cash Equivalents End Of Year | 5.69 | 6.77 | 5.28 | 3.76 | 0.00 |
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth